Morepen Laboratories logo

Morepen Laboratories

MOREPENLAB NSE
₹125.58 6.60 (4.99%)
Market Cap
₹6,881 Cr
P/E
48.86

Morepen Laboratories (MOREPENLAB) share price was ₹125.58 at the 28 Oct 2026 close; market capitalisation ₹6,881 Cr; P/E (TTM) 48.86; sector Healthcare. The share price rose 159.7% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 34.1% year on year to ₹570.1 Cr and net profit was ₹56 Cr, against ₹11 Cr a year earlier (compared with Jun 2025). Promoters held 35.65% of Morepen Laboratories in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 40/100 (Weak) as of 28 Oct 2026.

Close 28 Oct 2026 ₹125.58 +77.23 +159.73% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹6,881 Cr
P/E (TTM)
48.86
EBITDA
₹147 Cr
Return on Equity
7.67%
Debt to Equity
0.17
Book Value
₹25.21
EPS (TTM)
₹2.57
52W High
₹150.70
52W Low
₹33.05

Price-based figures as of 28 Oct 2026, 15:57 IST · EPS basis: Consolidated · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,757.5034.864,21,683 Cr5.050.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,558.5086.752,53,748 Cr15.140.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,557.0071.541,73,334 Cr9.430.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,181.90107.801,17,891 Cr22.240.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,175.5026.161,17,257 Cr4.330.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,335.4034.591,11,463 Cr2.870.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.6032.721,10,321 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Morepen Laboratories (this company)
₹125.5848.866,881 Cr4.980.15%7.67%9.43%2,312 Cr141 Cr
Median 8 companies₹1,561.5541.861,17,574 Cr5.020.47%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100. How it works →

As of 2026-10-28
v2.0.0
40 Weak
Overall score
Data confidence 100/100
surveillance:ASM4

Category scores

Quality Poor 27
Returns, margins, earnings quality 22%
Valuation Weak 42
Cheap vs sector & own history 24%
Growth Poor 32
Sales & profit trajectory 9%
Financial Health Good 56
Solvency, leverage, coverage 9%
Momentum Strong 99
Trend strength, vol-adjusted 12%
Ownership Strong 75
FII/DII/promoter flows 24%
Capped: a governance trigger overrides the fundamentals here (surveillance:ASM4 ≤ 40).

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Weaknesses

3
  • Stock is trading at 5.95 times its book value
  • The company has delivered a poor sales growth of 8.73% over past five years.
  • Company has a low return on equity of 9.26% over last 3 years.

Technical Indicators

Oscillators

BearishNeutralBullish

Bearish

Bearish
2
Neutral
7
Bullish
0

Overall

BearishNeutralBullish

Bullish

Bearish
3
Neutral
7
Bullish
9

Moving Averages

BearishNeutralBullish

Bullish

Bearish
1
Neutral
0
Bullish
9

Growth Rate

Revenue Growth
-0.16% lower than 3Y

change over 1 year

Net Income Growth
-18.98% lower than 3Y

change over 1 year

Cash Flow Change
1.81%

change over 1 year

EBITDA Margin Change
-23.57%

change over 1 year Operating margin 14% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
401
422
445
423
455
438
453
466
425
412
484
485
570
Expenses
375
388
394
375
404
394
417
424
401
381
438
460
488
Operating Profit
26
34
51
48
52
44
36
42
24
31
46
24
83
OPM %
7%
8%
11%
11%
11%
10%
8%
9%
6%
7%
10%
5%
14%
Other Income
2
3
4
4
3
5
5
5
4
30
4
8
5
Interest
0
0
2
1
1
1
1
5
4
4
4
4
5
Depreciation
8
8
8
10
6
2
5
16
9
11
10
6
8
PBT
21
29
44
42
48
46
35
26
16
46
35
23
75
Tax %
29%
26%
27%
32%
25%
24%
24%
21%
26%
10%
22%
33%
24%
Net Profit
15
21
32
29
36
35
27
20
11
41
28
16
56
EPS (₹)
0.29
0.42
0.63
0.55
0.71
0.64
0.49
0.37
0.2
0.75
0.5
0.29
1.03
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
401
485
595
607
769
853
1,188
1,547
1,418
1,690
1,812
1,806
1,951
Expenses
352
424
534
542
701
785
1,070
1,410
1,338
1,532
1,638
1,680
1,767
Operating Profit
48
62
61
65
68
69
119
137
80
159
174
126
184
OPM %
12%
13%
10%
11%
9%
8%
10%
9%
6%
9%
10%
7%
9%
Other Income
1
-3
4
4
4
9
12
10
6
14
18
47
48
Interest
9
10
8
4
2
2
2
-7
2
4
8
16
17
Depreciation
39
35
34
34
40
37
30
28
28
33
29
36
36
PBT
2
13
24
30
29
39
99
127
56
135
155
120
179
Tax %
6%
-1%
0%
0%
1%
14%
1%
20%
31%
29%
24%
20%
—
Net Profit
2
13
24
30
29
34
97
102
39
97
118
96
141
EPS (₹)
0.05
0.28
0.53
0.66
0.64
0.75
2.16
2.13
0.76
1.88
2.15
1.73
2.57
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
9%
12%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
90
90
90
90
90
90
90
96
102
102
110
110
Reserves
78
91
106
136
163
194
335
483
651
745
1,047
1,137
Borrowings
201
187
169
134
132
133
17
19
25
29
105
208
Other Liabilities
121
156
173
226
230
246
416
473
332
417
517
482
Total Liabilities
489
524
538
586
615
663
858
1,070
1,110
1,293
1,778
1,936
Fixed Assets
322
297
272
264
236
216
225
252
267
307
489
513
CWIP
0
0
0
0
0
0
2
14
17
24
28
22
Investments
0
0
0
0
0
1
1
0
0
1
85
124
Other Assets
167
227
266
321
379
446
631
804
827
960
1,176
1,277
Total Assets
489
524
538
586
615
663
858
1,070
1,110
1,293
1,778
1,936
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
51
50
41
63
17
11
51
-60
-91
73
32
33
Investing
-32
-27
-14
-27
-13
-12
-70
-32
-47
-83
-322
-126
Financing
-19
-27
-24
-38
0
5
47
66
144
5
300
97
Net Cash Flow
0
-4
3
-1
4
4
28
-26
6
-5
10
4
Free Cash Flow
46
41
31
37
6
-6
10
-127
-137
-8
-182
-127
CFO/OP
105
81
66
98
26
25
44
-26
-94
70
40
46
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
51
66
57
73
64
59
56
59
68
70
65
67
Inventory Days
55
51
65
76
69
91
82
96
87
85
94
88
Days Payable
126
140
125
173
124
113
98
90
87
101
114
103
Cash Conversion Cycle
-20
-23
-3
-24
9
37
40
65
69
54
45
53
Working Capital Days
-20
-10
-86
-62
-34
-8
17
55
98
94
107
118
ROCE %
3%
8%
9%
9%
8%
10%
23%
23%
8%
17%
15%
8%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Morepen Laboratories insights

73 extracted metrics + investor summaries across FY06–FY27.

Shareholding Pattern

DIIs1.71%Govt.0.01%Public46.71%FIIs3.43%Others12.48%Promot.35.65%As ofSep 2026

Documents

1
Concall - Aug 2026 Aug 2026
2
Concall - May 2026 May 2026
3
Concall - Feb 2026 Feb 2026
4
Concall - Nov 2025 Nov 2025
5
Concall - Aug 2025 Aug 2025

Frequently Asked Questions about Morepen Laboratories

What does Morepen Laboratories Ltd do?
Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products.[1]
Where is Morepen Laboratories Ltd (MOREPENLAB) listed?
Morepen Laboratories Ltd trades as MOREPENLAB on the NSE and under code 500288 on the BSE.
Which sector does Morepen Laboratories Ltd belong to?
Morepen Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Morepen Laboratories Ltd?
Morepen Laboratories Ltd has a market capitalisation of ₹6,881 Cr as of 28 Oct 2026, which places it in the Mid Cap band.
What is the PE ratio of Morepen Laboratories Ltd?
Morepen Laboratories Ltd trades at a PE ratio of 48.86 as of 28 Oct 2026, on earnings per share of ₹2.57, against a book value of ₹25.21 per share.
What is the 52-week high and low of Morepen Laboratories Ltd?
Over the last 52 weeks Morepen Laboratories Ltd has traded between ₹33.05 and ₹150.7 as of 28 Oct 2026.
Does Morepen Laboratories Ltd pay dividends?
Morepen Laboratories Ltd has a dividend yield of 0.15%.
What is the Return on Equity (ROE) of Morepen Laboratories Ltd?
Morepen Laboratories Ltd reported a return on equity of 7.67%. Its debt-to-equity ratio is 0.17.

Company Information

Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products.[1]

Website morepen.com
CEO Mr. Sushil Suri B.Sc., F.C.A.
Employees 1,814
Listed 1999-11-24
Face Value ₹ 2
Shares Outstanding 54,79,53,699

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/MOREPENLAB.md for Morepen Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month